Canada Markets closed

Protagenic Therapeutics, Inc. (PTIX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7600-0.1000 (-5.38%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.8600
Open1.8700
Bid1.7500 x 800
Ask1.7600 x 1400
Day's Range1.6500 - 1.8849
52 Week Range1.5500 - 4.8900
Volume430,700
Avg. Volume266,153
Market Cap25.773M
Beta (5Y Monthly)-0.46
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update

    NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the third quarter ended September 30, 2021. Recent Highlights Hosted a virtual science review to discuss the scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and Addiction. Replay available at www.protagenic.com.Hosted a key opinion l

  • GlobeNewswire

    Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET

    Scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and Addiction to be discussed NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a Scientific review of its programs designed for the treatment of patients with Depression, PTSD, Anxiety and Addiction. The review will take place o

  • GlobeNewswire

    Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update

    NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the second quarter ended June 30, 2021. Recent Highlights Closed a $13.2 million public offeringUp listed to the Nasdaq Capital MarketHosted a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addict